38.20
price down icon6.11%   -2.445
 
loading

Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie

pulisher
11:03 AM

PTC Therapeutics price target lowered to $57 from $65 at RBC Capital - Yahoo Finance

11:03 AM
pulisher
08:23 AM

Baker BROS. Advisors LP Buys Shares of 20,400 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

08:23 AM
pulisher
08:06 AM

PTC Therapeutics shares fall after Huntington’s study update - The Pharma Letter

08:06 AM
pulisher
05:11 AM

PTC's Huntington study was positive. Why did its stock fall? - Pharmaphorum

05:11 AM
pulisher
04:37 AM

Tudor Investment Corp ET AL Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

04:37 AM
pulisher
02:57 AM

First Trust Advisors LP Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

02:57 AM
pulisher
01:11 AM

PTCT Stock Dips 18% Despite Positive Huntington's Disease Study Results - GuruFocus

01:11 AM
pulisher
May 05, 2025

Raymond James Financial Inc. Invests $2.20 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 05, 2025
pulisher
May 05, 2025

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug - insights.citeline.com

May 05, 2025
pulisher
May 05, 2025

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Benzinga

May 05, 2025
pulisher
May 05, 2025

Leerink maintains $52 target on PTC Therapeutics stock By Investing.com - Investing.com India

May 05, 2025
pulisher
May 05, 2025

Leerink maintains $52 target on PTC Therapeutics stock - Investing.com

May 05, 2025
pulisher
May 05, 2025

PTC's Novartis-partnered Huntington's drug disappoints in mid-stage data reveal - FirstWord Pharma

May 05, 2025
pulisher
May 05, 2025

PTC’s Huntington’s study succeeds, but accelerated approval uncertain - Endpoints News

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics stock drops after Huntington’s study update - Investing.com Australia

May 05, 2025
pulisher
May 05, 2025

US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - AOL.com

May 05, 2025
pulisher
May 05, 2025

RBC Capital Adjusts Price Target for PTC Therapeutics (PTCT) After Study Data | PTCT Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics (PTCT) Announces Stock Option Grants for New Employees - GuruFocus

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics (PTCT) Faces Scrutiny Over Phase 2 Study Data | PTCT Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics Reports Positive Phase 2 Study Results - TipRanks

May 05, 2025
pulisher
May 05, 2025

PTC stock slides on new data for Huntington’s drug - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

PTC518 shows promise in Huntington’s disease trial By Investing.com - Investing.com Canada

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics (PTCT) Announces Promising Phase 2 Results for Huntington's Treatment | PTCT Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

PTC518 shows promise in Huntington’s disease trial - Investing.com

May 05, 2025
pulisher
May 05, 2025

PTC518 PIVOT-HD Study Achieves Primary Endpoint | PTCT Stock New - GuruFocus

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Schonfeld Strategic Advisors LLC Sells 66,953 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 05, 2025
pulisher
May 05, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

May 05, 2025
pulisher
May 05, 2025

Nebula Research & Development LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 05, 2025
pulisher
May 04, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by PDT Partners LLC - MarketBeat

May 04, 2025
pulisher
May 04, 2025

Price T Rowe Associates Inc. MD Trims Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 04, 2025
pulisher
May 03, 2025

Teachers Retirement System of The State of Kentucky Takes $940,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 03, 2025
pulisher
May 03, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Aquatic Capital Management LLC - MarketBeat

May 03, 2025
pulisher
May 03, 2025

Susquehanna Fundamental Investments LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 03, 2025
pulisher
May 03, 2025

What is Leerink Partnrs' Forecast for PTCT FY2026 Earnings? - MarketBeat

May 03, 2025
pulisher
May 03, 2025

Adage Capital Partners GP L.L.C. Increases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 03, 2025
pulisher
May 02, 2025

Tower Research Capital LLC TRC Buys 16,110 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 02, 2025
pulisher
May 02, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune

May 02, 2025
pulisher
May 01, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PTCT Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Invesco Ltd. Purchases 57,582 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Canada Pension Plan Investment Board Buys New Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

May 01, 2025
pulisher
May 01, 2025

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Wells Fargo & Company MN - MarketBeat

May 01, 2025
pulisher
Apr 29, 2025

Guggenheim Capital LLC Has $880,000 Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Apr 29, 2025
pulisher
Apr 29, 2025

Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance

Apr 29, 2025
$68.50
price down icon 5.02%
$20.91
price down icon 2.74%
$32.19
price down icon 2.12%
$24.55
price down icon 11.78%
$99.70
price down icon 1.20%
biotechnology ONC
$248.10
price down icon 1.85%
Capitalizzazione:     |  Volume (24 ore):